Doximity (DOCS) 주식 개요
는 미국 내 의료 전문가를 위한 디지털 플랫폼으로 운영되고 있습니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 DOCS에 대한 위험이 감지되지 않았습니다.
DOCS Community Fair Values
Create NarrativeSee what 84 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Doximity, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$24.98 |
| 52주 최고가 | US$76.51 |
| 52주 최저가 | US$20.55 |
| 베타 | 1.42 |
| 1개월 변동 | 8.94% |
| 3개월 변동 | -33.33% |
| 1년 변동 | -57.90% |
| 3년 변동 | -26.74% |
| 5년 변동 | n/a |
| IPO 이후 변동 | -52.87% |
최근 뉴스 및 업데이트
Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack
Apr 28
DOCS: Healthcare Moat And AI Tools Will Support Future Engagement
The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement
The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.
DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook
Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.Recent updates
Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack
Apr 28DOCS: Healthcare Moat And AI Tools Will Support Future Engagement
The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement
The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook
Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.
DOCS: AI Tools And Share Buybacks Will Drive Shares Higher
Doximity's updated fair value estimate has decreased to $56.00 from $68.90, reflecting analysts' reduced price targets from several firms, alongside ongoing support for the company's AI tools and healthcare marketing position. Analyst Commentary Street research on Doximity has been mixed, but there is a clear cluster of bullish analysts who see support for the story in healthcare marketing, AI tools and the company’s position with U.S. physicians.DOCS: AI Suite And Share Buybacks Will Shape A More Balanced Outlook
The analyst fair value estimate for Doximity has been revised to $25 from $50, reflecting a wave of reduced price targets across several firms, even as some analysts highlight potential from the company’s AI tools and broader healthcare marketing ecosystem. Analyst Commentary Recent research on Doximity shows a split tape, with some firms cutting price targets sharply while others highlight potential upside tied to the company’s tools and healthcare marketing position.DOCS: Pharma Ad Shift And Share Buybacks Will Drive Shares Higher
Analysts have reduced their Doximity fair value estimate from about US$83 to roughly US$69. This reflects updated expectations for more moderate revenue growth, slightly lower profit margins and a reduced future P/E multiple, even as several firms highlight the company’s strong position in digital healthcare marketing and its expanding product tools.Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%
Feb 06
DOCS: Rebased Sentiment And Strong Moat Will Support Future Engagement
Narrative Update on Doximity The analyst fair value estimate for Doximity has been adjusted from US$65.25 to about US$63.57 as analysts factor in lower target prices, along with continued confidence in the company's moat, market share gains, and higher reported ROI compared with other digital healthcare marketing platforms. Analyst Commentary Recent research on Doximity highlights a mix of optimism and caution as analysts update ratings and price targets while reassessing growth, execution, and risk pricing.DOCS: Rebased Sentiment And Budget Shifts Will Support Stronger Engagement
Our updated analyst price target framework for Doximity moves fair value from US$71.11 to US$65.25 as analysts recalibrate growth, discount rate and forward P/E assumptions, while still pointing to strengthening platform engagement and expanding tools such as OpenEvidence, as well as what several describe as a defensible competitive position in healthcare professional marketing. Analyst Commentary Recent Street research on Doximity reflects a mix of optimism around the core franchise and its tools such as OpenEvidence, alongside a more cautious reset on valuation and competitive risk.DOCS: Budget Flush And Pharma Ad Shift Will Drive Shares Higher
We modestly raised our Doximity price target to $83.00 per share from $62.00, as analysts highlight improving long term growth visibility, accelerating video driven revenue momentum, and an increasingly compelling risk reward profile following the recent pullback, despite ongoing debate around pharma digital ad trends. Analyst Commentary Bullish analysts are increasingly highlighting Doximity as a high conviction idea following the post earnings selloff, pointing to a more attractive entry point relative to its vertical software peers.DOCS: Budget Flush And Ad Shift Will Drive Shares Higher
Analysts have lifted their Doximity fair value estimate to $83.00 from $78.58, reflecting stronger expected revenue growth and improving long term growth visibility, which they believe more than offset lower margin assumptions and a higher required return. Analyst Commentary Bullish analysts highlight that the recent pullback in Doximity shares has created a compelling entry point, with the stock now trading at what they view as an unjustified discount to the broader vertical software peer group.Doximity, Inc. (NYSE:DOCS) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Nov 14DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks
Analysts have modestly increased their price target for Doximity, raising the estimate from $70.72 to $71.11 per share. They cite stronger revenue momentum, which is supported by recent upgrades and expectations for higher provider-driven growth.AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Analysts have raised their price target for Doximity from $69.50 to $70.72. They cited slightly improved profit margin forecasts and increased confidence in the company’s platform engagement as advertising trends evolve.AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity's analyst price target has increased from $68.67 to $69.50 per share. This change reflects analysts' positive view on strong business momentum, promising AI initiatives, and a conservative outlook for fiscal 2026 revenue growth.AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity’s price target was raised modestly to $68.67 as analysts pointed to robust Q1 results, AI-driven strategy enhancements, and conservative guidance as drivers of sustained business momentum. Analyst Commentary Bullish analysts cite strong Q1 results and upwardly revised guidance as evidence of solid business momentum.At US$67.94, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?
Sep 02We Think Doximity's (NYSE:DOCS) Profit Is Only A Baseline For What They Can Achieve
Aug 15AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity’s fair value outlook has improved as reflected by a higher consensus price target, despite a notable contraction in net profit margin and a rising future P/E multiple signaling higher growth expectations. What's in the News Doximity provided revenue guidance for FY26 of $628–636 million and Q2 FY26 of $157–158 million.Getting In Cheap On Doximity, Inc. (NYSE:DOCS) Is Unlikely
Jul 08With EPS Growth And More, Doximity (NYSE:DOCS) Makes An Interesting Case
Jun 23At US$52.56, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?
May 17Calculating The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)
May 01Shareholders Are Optimistic That Doximity (NYSE:DOCS) Will Multiply In Value
Apr 04What Doximity, Inc.'s (NYSE:DOCS) 28% Share Price Gain Is Not Telling You
Feb 23Doximity Q3 Earnings: Outpacing Even Management's Expectations
Feb 10When Should You Buy Doximity, Inc. (NYSE:DOCS)?
Jan 24Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution
Jan 13Here's Why We Think Doximity (NYSE:DOCS) Is Well Worth Watching
Jan 06Doximity: Strong Fundamentals And Growth Potential Makes It Attractive
Dec 06Doximity (NYSE:DOCS) Knows How To Allocate Capital
Dec 01Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%
Nov 13Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?
Nov 02Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?
Oct 15Doximity: Downgrade To Hold On Valuation Concerns
Oct 03Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors
Sep 23
Generative AI And Digital Health Innovations Fuel Robust Revenue Growth And Market Expansion
Accelerating adoption of new products and a client portal, alongside strategic positioning with top clients, suggests sustained revenue expansion.There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump
Aug 18주주 수익률
| DOCS | US Healthcare Services | US 시장 | |
|---|---|---|---|
| 7D | 4.0% | 2.7% | 0.8% |
| 1Y | -57.9% | -37.4% | 27.7% |
수익률 대 산업: DOCS은 지난 1년 동안 -37.4%의 수익을 기록한 US Healthcare Services 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: DOCS은 지난 1년 동안 27.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| DOCS volatility | |
|---|---|
| DOCS Average Weekly Movement | 7.9% |
| Healthcare Services Industry Average Movement | 10.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
안정적인 주가: DOCS는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: DOCS의 주간 변동성(8%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2010 | 830 | Jeff Tangney | www.doximity.com |
는 미국 내 의료 전문가를 위한 디지털 플랫폼으로 운영되고 있습니다. 이 플랫폼은 회원들에게 의료용으로 제작된 디지털 도구를 제공하여 동료와 협업하고, 최신 의학 뉴스와 연구 결과를 최신 상태로 유지하고, 경력 및 당직 일정을 관리하고, 문서 및 행정 서류 작업을 간소화하고, 가상 환자 방문을 수행할 수 있도록 지원합니다. 이 회사는 주로 의사, 전문간호사, 의사 보조원, 의대생, 제약 제조업체 및 의료 시스템을 대상으로 서비스를 제공합니다.
Doximity, Inc. 기초 지표 요약
| DOCS 기초 통계 | |
|---|---|
| 시가총액 | US$4.51b |
| 순이익 (TTM) | US$239.40m |
| 매출 (TTM) | US$637.78m |
19.3x
주가수익비율(P/E)7.2x
주가매출비율(P/S)DOCS는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| DOCS 손익계산서 (TTM) | |
|---|---|
| 매출 | US$637.78m |
| 매출원가 | US$65.39m |
| 총이익 | US$572.39m |
| 기타 비용 | US$333.00m |
| 순이익 | US$239.40m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
May 13, 2026
| 주당순이익(EPS) | 1.30 |
| 총이익률 | 89.75% |
| 순이익률 | 37.54% |
| 부채/자본 비율 | 0% |
DOCS의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/01 12:12 |
| 종가 | 2026/05/01 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Doximity, Inc.는 32명의 분석가가 다루고 있습니다. 이 중 22명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Vikram Kesavabhotla | Baird |
| Glen Santangelo | Barclays |
| Nisala Weerasuriya | Berenberg |